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Editor:
We commend Dr Xing and colleagues for their interesting 
comparative analysis of treatment modalities for small renal 
masses in the July 2018 issue of Radiology (1). This is clearly 
an important clinical question. The authors made use of pro-
pensity score–matched observational data from the Surveil-
lance, Epidemiology, and End Results (SEER)–Medicare 
database adjusted for 17 variables to compare cancer-specific 
and overall survival with partial nephrectomy (PN), radical 
nephrectomy (RN), thermal ablation (TA), and active sur-
veillance (AS).
Propensity score methods allow for the minimization 
of baseline imbalances across treatment groups. In particu-
lar, propensity score matching generates sets of treated and 
untreated subjects with similar known covariates (2). Al-
though cancer-specific survival analyses supported PN and 
TA over AS in the study by Dr Xing and colleagues (1), 
the effect size (ie, absolute change in survival rates) is small 
even at 9 years (range, 1.4%–2.5%). Plus, overall survival, 
a surrogate for general health status, had large differences 
across all treatment options and AS (range, 5.9%–7.7%). 
This sanity check supports the existence of unknown and 
unaccounted confounding factors that limit the validity of 
the results.
Observational data may be better than no data, but we 
must not forget that while such quasi-experimental designs 
are a useful exploratory tool, only randomized controlled 
trials will allow for the balancing of unmeasured confound-
ers and the estimation of unbiased causal treatment effects. 
Unfortunately, the only clinical trial to date to attempt a 
randomized comparison between AS and other treatment 
modalities, the SURAB study (a randomized study compar-
ing ablation with active surveillance in the management of 
incidentally diagnosed small renal tumors; trial registration 
number ISRCTN31161700), failed to successfully recruit 
enough participants (3). Alternative, pragmatic trial designs, 
such as cohort embedded randomized studies, are needed 
to offer feasible alternatives to deliver high-quality unbiased 
evidence for the management of small renal masses.
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We thank Dr Neves and colleagues for their letter regard-
ing our study (1). We agree that observed differences in 
outcomes between currently available treatment modali-
ties for small renal masses bears comparison in random-
ized controlled trials or pragmatic trials to minimize un-
known discrepancies at baseline. As initial management, 
AS is currently considered safe for older and/or sicker 
patients and those with very small masses (<2 cm) (2). 
However, given the paucity of prospective studies com-
paring the oncologic outcomes of AS to other modali-
ties, observational data as presented in our study serve to 
provide insight into the possible benefits of intervention, 
including long-term outcomes, within the limitations of 
the database and framework of assumptions required in 
propensity score matching.
To better understand the impact of possible unmea-
sured confounding factors when comparing PN, RN, and 
TA with AS, we further performed formal sensitivity analy-
sis on our findings. Based on methods set forth by Rosen-
baum (3,4), we observed a high  (gamma) value of greater 
than 5 for differences in both cancer-specific survival and 
overall survival when PN, RN, and TA were compared 
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individually with AS. Similarly high  values were observed in 
other direct comparisons, including PN or RN versus TA. These 
results suggest that the comparisons made were insensitive to un-
known confounding factors.
As mentioned in our Discussion, we acknowledge that the 
discrepancy in the cancer-specific survival rate for PN and TA 
over AS (range, 1.4%–2.5%) as compared with a difference in 
overall survival of between 5.8% and 7.7% at 9 years may be 
due to the lack of clarity with regard to whether all patients des-
ignated to AS underwent adequate surveillance. Here, we are 
unfortunately further limited by the availability of information 
present in the SEER-Medicare database, which does not offer 
specific, standardized coding for AS. As a result, it is not possible 
to use registry data alone to clearly differentiate between patients 
who underwent AS with structured observation protocols, such 
as that of the Delayed Intervention and Surveillance for Small 
Renal Masses, or DISSRM, Registry (5), and those who delayed 
intervention due to other factors. Such limitations would be 
readily addressed in urgently needed prospective, randomized 
comparisons between AS and intervention, which would go a 
long way toward answering the questions that remain with re-
gard to optimal therapeutic protocols for small renal masses.
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